Clinical trial NCT05988515: AI-Assisted Treatment for Residual Speech Sound Disorders
Official title: AI-Assisted Treatment for Residual Speech Sound Disorders
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Speech Sound Disorder
Lead sponsor: Syracuse University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: State University of New York - Upstate Medical University
name: National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted: 2023-08-14
Enrollment: 26
Sex: ALL
Minimum age (years): 9
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomized across two conditions, CONCURRENT and SEQUENTIAL

Participants randomized to receive CONCURRENT treatment will receive speech lessons with a human clinician once per week for five weeks, along with 3 sessions per week of parent-supervised Chaining-AI (15 Chaining-AI sessions). Therefore, clinician-led and Chaining-AI are completed concurrently.

Participants randomized to receive SEQUENTIAL treatment will receive speech lessons with a human clinician once per week for five weeks, followed by three sessions per week of parent-supervised Chaining-AI for the NEXT five weeks. Therefore, clinician-led and Chaining-AI are completed sequentially.
Primary purpose: TREATMENT

Brief summary: The goal of this randomized-controlled trial is to determine how artificial intelligence-assisted home practice may enhance speech learning of the "r" sound in school-age children with residual speech sound disorders. All child participants will receive 1 speech lesson per week, via telepractice, for 5 weeks with a human speech-language clinician. Some participants will receive 3 speech sessions per week with an Artificial Intelligence (AI)-clinician during the same 5 weeks as the human clinician sessions (CONCURRENT treatment order group), whereas others will receive 3 speech sessions per week with an AI-clinician after the human clinician sessions end (SEQUENTIAL treatment order group.

Detailed description: Artificial Intelligence-assisted treatment that detects mispronunciations within an evidence-based motor learning framework could increase access to sufficiently intense, efficacious treatment despite provider shortages. A successful Artificial intelligencesystem that can predict the clinical gold standard of trained listeners' perceptions could not only improve access to clinical care but also mitigate known confounds to accurate clinical feedback, including clinical experience and drift due to increasing familiarity between the speaker and listener. The Artificial intelligence tool used in this study includes a speech classifier trained to predict clinician judgment of American English "r" that is integrated into an existing evidence-based treatment software called Speech Motor Chaining.

Eligibility criteria: Inclusion Criteria:

* Must speak a rhotic dialect of American English as a dominant language.
* Must have begun learning English by at least the age of 3 years.
* Must be between 9;0 to 17;11 years of age.
* Must have reported difficulty with /ɹ/ production.
* Must have reported hearing within normal limits.
* Must receive a Scaled Score of 5 or above on both the Listening Comprehension and Story Retelling subtests from the Test of Integrated Language \& Literacy Skills (TILLS).
* Must receive a percentile score of 8 or below on the Goldman-Fristoe Test of Articulation-3 (GFTA-3) Sounds in Words subtest.
* Must have 1 scorable response with 5+ consecutive correct /pataka/ with \> 3.4 syllables per second in the MRR-Tri task of the Maximum Performance Tasks OR must demonstrate no childhood apraxia of speech (CAS-only) features in BOTH articulatory and rate/prosody domains of the ProCAD.
* Must score \<40% accurate based on word-level items from our /ɹ/ probe list.
* Must score \>=15% accuracy on /ɹ/ on 45 syllables following Dynamic Assessment.
* Must express interest in changing their /ɹ/ production.
* Must have oral structure and function that are appropriate for /ɹ/ production.
* Must have access to broadband internet with videoconferencing capabilities

Exclusion Criteria:

* Must have no known history of autism spectrum disorder, Down Syndrome, cerebral palsy, intellectual disability, permanent hearing loss, epilepsy/antiepileptic medication, or brain injury/neurosurgery/stroke.
* Must not have diagnosis of attention deficit disorder, attention deficit hyperactivity disorder, Tourette's, or Obsessive-compulsive disorder.
* Must have no orthodontic appliances that block the roof of the mouth (e.g., palate expanders).
* Must not have current cleft palate, fluency disorder, or voice disorder.
* Must not demonstrate childhood apraxia of speech (CAS-only) features in BOTH articulatory and rate/prosody domains of the ProCAD.

Primary outcomes:
measure: Change in percent correct for the /ɹ/ sound in untreated words, rated by blinded listeners.
timeFrame: Before the initiation of treatment and again 5 weeks later.
Secondary outcomes:
measure: Retention of percent correct for the /ɹ/ sound in untreated words, rated by blinded listeners.
timeFrame: Before the initiation of treatment and again 10 weeks later.
measure: Change in percent correct for the /ɹ/ sound in untreated words, rated by blinded listeners.
timeFrame: After 5 weeks of treatment and again 10 weeks later.
measure: Survey evaluating impacts of speech disorder on participants' social, emotional, and academic well-being.
timeFrame: Before the initiation of treatment and again 5 weeks later.
measure: Change in percent correct for the /ɹ/ sound in practiced words, rated by blinded listeners.
timeFrame: Before the initiation of treatment and again 5 weeks later.
measure: Change in percent correct for the /ɹ/ sound in practiced words, rated by blinded listeners.
timeFrame: Before the initiation of treatment and again 10 weeks later.
measure: Change in percent correct for the /ɹ/ sound in practiced words, rated by blinded listeners.
timeFrame: After 5 weeks of treatment and again 10 weeks later.
Other outcomes:
Locations:
city: Syracuse
country: United States
facility: Syracuse University
state: New York
Study officials:
References: